From: Survival in Idiopathic pulmonary fibrosis acute exacerbations: the non-steroid approach
Variable | HR | 95 % CI | p-value |
---|---|---|---|
Age | 0.968 | 0.919–1.020 | 0.221 |
Gender | 1.927 | 0.600–6.186 | 0.270 |
Smoking (pack-years) | 1.000 | 0.980–1.020 | 0.996 |
FEV1 (% predicted) | 1.000 | 0.941–1.063 | 0.990 |
FVC (% predicted) | 1.001 | 0.961–1.043 | 0.943 |
TLC (% predicted) | 1.034 | 0.976–1.096 | 0.252 |
DLCO (% predicted) | 1.044 | 0.963–1.319 | 0.293 |
Charlson comorbidity index | 0.729 | 0.466–1.143 | 0.169 |
LTOT | 1.138 | 0.356–3.631 | 0.829 |
Pattern of GGO in HRCT | 1.650 | 0.737–3.696 | 0.223 |
PO2/fiO2 | 0.990 | 0.980–1.001 | 0.067 |
NIMV | 2.014 | 0.449–9.039 | 0.361 |
Mechanical ventilation | 1.966 | 0.646–5.992 | 0.234 |
Disease duration | 1.014 | 0.995–1.034 | 0.156 |
Previous corticosteroid use (all exacerbation events) | 3.544 | 1.090–11.514 | 0.035 |
Previous corticosteroid use (unique patients) | 1.642 | 0.441–6.119 | 0.460 |
BAL performed | 0.676 | 0.188–2.427 | 0.548 |
6MWD | 0.999 | 0.994–1.005 | 0.918 |